HI-Bio Presents Positive Interim Data from P-II (IGNAZ) Trial of Felzartamab for IgAN at 61st ERA Congress 2024
Shots:
- HI-Bio presented positive interim results from P-II (IGNAZ) study at 61st ERA Congress 2024, evaluating Felzartamab to treat high-risk IgAN adult patients (n=54) in 4 groups; 3 arms with 2, 5, and 9 doses of Felzartamab (16mg/kg; IV) and one arm with PBO for over 24wks
- 9 dose regimen patients over 5mos. showed a decrease in proteinuria levels, ~50% mean reduction in UPCR at 24mos. maintained for >18mos. after the last dose, stabilized kidney function, prolonged pharmacodynamic effect of IgA reduction was observed with IgG and IgM levels recovery
- Felzartamab is a human monoclonal antibody directed against CD38. Complete data of the IGNAZ study is anticipated at the end of 2024 and expected to be submitted in a peer-reviewed forum
Ref: HI-Bio | Image: HI-Bio
Related News: HI-Bio Reports P-II (M-PLACE) and (NewPLACE) Studies Results of Felzartamab to Treat Primary Membranous Nephropathy
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
An avid reader and a dedicated learner, Prince works as a Content Writer at PharmaShots. Prince possesses an exceptional quality of breaking down the barriers of words by simplifying the terms in digestible chunks to make content readable and comprehensible. Prince likes to read books and loves to spend his free time learning and upskilling himself.
